Latest Articles
Cartherics opens advanced cell therapy manufacturing facility in Victoria - Australian Manufacturing
Cartherics opens advanced cell therapy manufacturing facility in Victoria Australian Manufacturing
Published: Aug. 7, 2025, 1:04 a.m.
NICE approves first immunotherapy combination for endometrial cancer - Wired Gov
NICE approves first immunotherapy combination for endometrial cancer Wired Gov
Published: Aug. 6, 2025, 1:13 p.m.
Cartherics unveils cleanroom facility for cell therapy manufacturing - Med-Tech Insights
Cartherics unveils cleanroom facility for cell therapy manufacturing Med-Tech Insights
Published: Aug. 6, 2025, 12:25 p.m.
First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central
First immunotherapy combination for endometrial cancer approved by NICE Oncology Central
Published: Aug. 6, 2025, 11:18 a.m.
First immunotherapy for advanced endometrial cancer approved in the UK - Open Access Government
First immunotherapy for advanced endometrial cancer approved in the UK Open Access Government
Published: Aug. 6, 2025, 8:50 a.m.
Cartherics unveils state-of-the-art cleanroom facility for cell therapy manufacturing - medianet.com.au
Cartherics unveils state-of-the-art cleanroom facility for cell therapy manufacturing medianet.com.au
Published: Aug. 6, 2025, 5:24 a.m.
NICE approves first immunotherapy combination for endometrial cancer - NICE website
NICE approves first immunotherapy combination for endometrial cancer NICE website
Published: Aug. 5, 2025, 11 p.m.
Optimizing Therapy for MMR-Proficient Endometrial Cancer - OncLive
Optimizing Therapy for MMR-Proficient Endometrial Cancer OncLive
Published: July 31, 2025, 2:27 p.m.
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights - Cureus
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights Cureus
Published: July 30, 2025, 7:21 a.m.
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight - The Malaysian Reserve
B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight The Malaysian Reserve
Published: July 24, 2025, 10:55 p.m.
Link copied to clipboard!